An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
A partnering deal with J&J worth $300m in upfront cash, over a largely ignored second pipeline candidate, should put the Belgian biotech firmly on the map.
Promising mid-stage data in a third indication for efgartigimod have given the Belgian company another boost.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.